ImmunoSource
ActiveSummary
ImmunoSource has been active since 1993 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €1.4m and a net result of €92,739. Equity grew by about 3.9% per year on average since 2019. In 2025 it fell by 1.9%. Its solvency ranks better than 95% of 5,724 sector peers (NACE 96, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
Overview
Overview
Official details
Source: KBO- Status
- Active since 15-10-1993 Normal situation
- Activity
- Other personal services NACE 96999
- Joint committees
- 116 Paritair Comité voor de scheikundige nijverheid
- 207 Paritair Comité voor de bedienden uit de scheikundige nijverheid · annual accounts 31-07-2025
- Establishment unit
- 2.064.166.631 2980 Zoersel, since 29-10-1993
- Financial year end
- 31 July
- Peppol
- Reachable since 30-09-2025
Financial position
- Bankruptcy probabilitywithin 12 months
- < 0.1%
Annual accounts to 31-07-2025
- Gross margin
- €88,294
- ▼ 31.5%
- Turnover
- ≈ €230,000
- estimated
- Profit
- €92,739
- ▼ 2.9%
- Equity
- €1.4m
- ▼ 1.9%
- Total assets
- €1.4m
- ▼ 4.2%
Score breakdownlowers riskLiquidity: current ratio 53.11, cash €354,739Equity €1.4m (98.2% of total assets)Founded in 1993Size: total assets €1.4mShow the evidence
Checked score
Score 2025
95
/ 100
Excellent
Probability in this band: under 0.55%
Financially stronger than 62% of micro companies in personal services (NACE 96)
Financial strength · tick: 2024
Strong
Solvency
100=
equity 98.2% of total assets
Liquidity
81+9
short-term debt 1.8% · cash 24.9%
Profitability
46-19
return on assets 6.5%
Bankruptcy probability within 12 months
< 0.1%
Very low
0%0.5%1.5%4%10%≥ 25%
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: < 0.1%
01-2025: < 0.1%● unchanged vs 12-2024
02-2025: < 0.1%● unchanged vs 01-2025
03-2025: < 0.1%● unchanged vs 02-2025
04-2025: < 0.1%● unchanged vs 03-2025
05-2025: < 0.1%● unchanged vs 04-2025
06-2025: < 0.1%● unchanged vs 05-2025
07-2025: < 0.1%● unchanged vs 06-2025
08-2025: < 0.1%● unchanged vs 07-2025
09-2025: < 0.1%● unchanged vs 08-2025
10-2025: < 0.1%● unchanged vs 09-2025
11-2025: < 0.1%● unchanged vs 10-2025
12-2025: < 0.1%● unchanged vs 11-2025
01-2026: < 0.1%● unchanged vs 12-2025
02-2026: < 0.1%● unchanged vs 01-2026highest value
03-2026: < 0.1%● unchanged vs 02-2026
04-2026: < 0.1%● unchanged vs 03-2026
05-2026: < 0.1%● unchanged vs 04-2026
06-2026: < 0.1%● unchanged vs 05-2026
07-2026: < 0.1%● unchanged vs 06-2026
08-2026: < 0.1%● unchanged vs 07-2026lowest value
09-2026: < 0.1%● unchanged vs 08-2026
10-2026: < 0.1%● unchanged vs 09-2026
11-2026: < 0.1%● unchanged vs 10-2026
Credit of up to €130,000 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 53.11 (23.38 in 2024), above the usual 1.5. Short-term debt is 1.8% and cash 24.9% of total assets. 1.8% of the assets are financed with debt and provisions.
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 96, micro). It does better than 93% of them on solvency, 83% on liquidity, 34% on profitability and 37% on growth.
The bankruptcy probability was computed on 04-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-07-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Five signals.
lowers riskneutral
neutral · Latest accounts filed on time
The financial year that closed on 31-07-2025 was due by 28-02-2026 and was filed on 10-02-2026, 18 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
18 days early
2024
8 days early
2023
1 day early
2022
on the day
2021
17 days early
2020
2 days early
2019
1 day early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 7 days before the deadline. In the sector (NACE 96), the median for financial year 2024 was on the deadline day, and 48% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The financial year that closed on 31-07-2026 is due by 28-02-2027. Nothing is late today. The company usually files around 20 February (5 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
31-07-2026 year end05-11-2026 today28-02-2027 deadline
Financials
Financials · financial year 2025, micro format
Annual accounts 2025 filed on 10-02-2026 PDF all 31 filings
Turnover
≈ €230,000
Estimated: probably between €160,000 and €290,000
Total assets
€1.4m▼ 4.2%
2024 · €1.5m
Net result
€92,739▼ 2.9%
2024 · €95,521
Working capital
€1.4m▼ 1.1%
2024 · €1.4m
In the rankings
#4 company by total assets in Schilde, Other services sector#4 company by equity in Schilde, Other services sector#5 oldest company in Schilde, Other services sector
Multi-year overview
2019 to 2025, 7 financial yearsOperating result
€70,062
▼ 35.9%
2025
20192025
Net result
€92,739
▼ 2.9%
2025
highest quarter of the sector
20192025
Equity
€1.4m
▼ 1.9%
2025
highest quarter of the sector
20192025
Total assets
€1.4m
▼ 4.2%
2025
highest quarter of the sector
20192025
Debt
€26,238
▼ 57.5%
2025
20192025
Working capital
€1.4m
▼ 1.1%
2025
highest quarter of the sector
20192025
Solvency
98.2%
▲ 2.3pp
2025
highest quarter of the sector
20192025
Current ratio
53.11
▲ 29.73
2025
highest quarter of the sector
20192025
Return on assets (ROA)
6.5%
▲ 0.1pp
2025
middle half of the sector
20192025
Every figure per financial year
Every figure with its change against the financial year before
favourable
unfavourable
Line2019202020212022202320242025
Operating result€0.2m-€0.1m▼ 2.7%€0.2m▲ 30.5%€0.3m▲ 28.1%€0.1m▼ 51.0%€0.1m▼ 10.9%€0.07m▼ 35.9%
Net result€0.2m-€0.2mabove the sector's middle half▼ 4.3%€0.2mabove the sector's middle half▲ 24.4%€0.2mabove the sector's middle half▼ 6.1%€0.1mabove the sector's middle half▼ 25.4%€0.1mabove the sector's middle half▼ 29.2%€0.09mabove the sector's middle half▼ 2.9%
Equity€1.1m-€1.2mabove the sector's middle half▲ 11.7%€1.3mabove the sector's middle half▲ 8.2%€1.4mabove the sector's middle half▲ 5.4%€1.4mabove the sector's middle half▲ 1.4%€1.4mabove the sector's middle half▼ 0.6%€1.4mabove the sector's middle half▼ 1.9%
Total assets€1.3m-€1.4mabove the sector's middle half▲ 8.4%€1.5mabove the sector's middle half▲ 9.1%€1.6mabove the sector's middle half▲ 4.9%€1.5mabove the sector's middle half▼ 3.6%€1.5mabove the sector's middle half▼ 0.4%€1.4mabove the sector's middle half▼ 4.2%
Debt€0.1m-€0.1m▼ 18.2%€0.1m▲ 18.5%€0.1m▼ 0.1%€0.06m▼ 56.2%€0.06m▲ 4.3%€0.03m▼ 57.5%
Working capital€1.0m-€1.1mabove the sector's middle half▲ 14.1%€1.3mabove the sector's middle half▲ 10.1%€1.3mabove the sector's middle half▲ 7.2%€1.4mabove the sector's middle half▲ 2.2%€1.4mabove the sector's middle half▲ 0.6%€1.4mabove the sector's middle half▼ 1.1%
Solvency88.8%-91.6%above the sector's middle half▲ 2.7pp90.8%above the sector's middle half▼ 0.7pp91.3%above the sector's middle half▲ 0.4pp96.0%above the sector's middle half▲ 4.8pp95.8%above the sector's middle half▼ 0.2pp98.2%above the sector's middle half▲ 2.3pp
Current ratio8.48-10.97above the sector's middle half▲ 2.4910.26above the sector's middle half▼ 0.7110.94above the sector's middle half▲ 0.6824.20above the sector's middle half▲ 13.2623.38above the sector's middle half▼ 0.8353.11above the sector's middle half▲ 29.73
Return on assets (ROA)12.9%-11.4%within the sector's middle half▼ 1.5pp13.0%within the sector's middle half▲ 1.6pp11.7%within the sector's middle half▼ 1.4pp9.0%within the sector's middle half▼ 2.6pp6.4%within the sector's middle half▼ 2.6pp6.5%within the sector's middle half▲ 0.1pp
above
within
below
The sector band is the middle half of the companies in Personal service activities (NACE 96). A quarter of them sit below it, a quarter above. Each year counts only accounts in the same format, and only where there are at least 30.
The operating result for 2025 is 36% lower than in 2024 and the lowest since 2019. It is the third fall in a row.
Turnover and EBIT margin are not published. The abbreviated or micro format does not require them. The turnover shown is an estimate from the gross margin.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €1.4m
Fixed assets
€33,629 ▼ 25.8%
Current assets
€1.4m ▼ 3.5%
Equity and liabilities €1.4m
Equity
€1.4m ▼ 1.9%
Debt
€26,238 ▼ 57.5%
Debt's share of the balance-sheet total falls from 4.2% to 1.8%. Equity and debt are lower.
Key figures and ratios
EBITDA
€86,181▼
2024 · €126,467
Cash flow
€108,858▼
2024 · €112,632
Quick ratio
53.06▲
2024 · 23.35
Debt to equity
0.02▼
2024 · 0.04
ROE
6.6%▼
2024 · 6.7%
Interest coverage
2.32▼
2024 · 4.54
Debt ≤ 1 year
€26,194▼
2024 · €61,699
Income taxes
€22,216▼
2024 · €40,297
Green means a favourable move, even when the figure itself falls, as with debt or debt to equity.
Investments
| Item | 31-07-2022 | 31-07-2023 | 31-07-2024 | 31-07-2025 |
|---|---|---|---|---|
| Tangible fixed assets | - | - | - | €4,455 |
| Intangible fixed assets | - | €5,765 | - | - |
| Depreciation and write-downs of the year | €18,119 | €15,760 | €17,111 | €16,120 |
Source: notes to the 2022 to 2025 annual accounts (statement of fixed assets)
Annual accounts
| Line | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|
| Non-recurring operating income76A | - | - | - | €5,913 | - | - | €9,090 | - |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €17,055 | €16,637 | €17,514 | €18,119 | €15,760 | €17,111 | €16,120 | ▼ 5.8% |
| Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4 | - | - | - | -€179 | -€179 | -€179 | - | - |
| Other operating charges640/8 | - | - | - | €1,942 | €2,012 | €2,571 | €2,113 | ▼ 17.8% |
| Gross operating margin9900 | €172,524 | €166,826 | €215,649 | €270,257 | €140,328 | €128,859 | €88,294 | ▼ 31.5% |
| Operating profit (loss)9901 | €153,920 | €149,712 | €195,404 | €250,374 | €122,736 | €109,356 | €70,062 | ▼ 35.9% |
| Financial income75/76B | - | - | - | €55,766 | €74,752 | €54,307 | €82,100 | ▲ 51.2% |
| Recurring financial income75 | €85,155 | €105,485 | €67,823 | €55,766 | €74,752 | €54,307 | €82,100 | ▲ 51.2% |
| Financial charges65/66B | - | - | - | €42,523 | €29,621 | €27,844 | €37,207 | ▲ 33.6% |
| Recurring financial charges65 | €23,995 | €49,998 | €35,223 | €42,523 | €29,621 | €27,844 | €37,207 | ▲ 33.6% |
| Profit (loss) for the period before taxes9903 | €215,079 | €205,200 | €228,003 | €263,618 | €167,867 | €135,819 | €114,954 | ▼ 15.4% |
| Income taxes67/77 | €53,317 | €50,355 | €35,361 | €82,805 | €32,989 | €40,297 | €22,216 | ▼ 44.9% |
| Profit (loss) for the period9904 | €161,763 | €154,845 | €192,642 | €180,813 | €134,878 | €95,521 | €92,739 | ▼ 2.9% |
| Transfer from tax-exempt reserves789 | - | - | - | €56,250 | - | - | - | - |
| Profit (loss) for the period to be appropriated9905 | €161,763 | €154,845 | €192,642 | €237,063 | €134,878 | €95,521 | €92,739 | ▼ 2.9% |
| Line | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Total assets20/58 | €1.3m | €1.4m | €1.5m | €1.6m | €1.5m | €1.5m | €1.4m | ▼ 4.2% |
| Fixed assets21/28 | €0.1m | €0.1m | €0.09m | €0.07m | €0.06m | €0.05m | €0.03m | ▼ 25.8% |
| Intangible fixed assets21 | - | - | - | - | €0.006m | €0.004m | €0.002m | ▼ 52.5% |
| Tangible fixed assets22/27 | €0.1m | €0.1m | €0.09m | €0.07m | €0.06m | €0.04m | €0.03m | ▼ 23.4% |
| Land and buildings22 | - | - | - | €0.07m | €0.05m | €0.04m | €0.03m | ▼ 33.1% |
| Plant, machinery and equipment23 | - | - | - | €0.002m | €0.002m | €0.001m | €0.003m | ▲ 110% |
| Furniture and vehicles24 | - | - | - | €0.001m | €128 | - | €0.002m | - |
| Other tangible fixed assets26 | - | - | - | €0.003m | €0.001m | - | - | - |
| Current assets29/58 | €1.1m | €1.3m | €1.4m | €1.5m | €1.4m | €1.4m | €1.4m | ▼ 3.5% |
| Stocks and contracts in progress3 | €0.03m | €0.02m | €0.004m | €0.002m | €0.001m | €0.002m | €0.001m | ▼ 18.0% |
| Stocks30/36 | - | - | - | €0.002m | €0.001m | €0.002m | €0.001m | ▼ 18.0% |
| Amounts receivable within one year40/41 | €0.07m | €0.03m | €0.1m | €0.09m | €0.04m | €0.08m | €0.02m | ▼ 78.9% |
| Trade receivables40 | - | - | - | €0.09m | €0.04m | €0.08m | €0.02m | ▼ 78.9% |
| Current investments50/53 | €0.6m | €0.6m | €0.6m | €0.8m | €0.9m | €1.1m | €1.0m | ▼ 7.3% |
| Cash at bank and in hand54/58 | €0.5m | €0.6m | €0.7m | €0.6m | €0.5m | €0.3m | €0.4m | ▲ 32.8% |
| Deferred charges and accrued income490/1 | - | - | - | €0.001m | €0.001m | €0.001m | €0.002m | ▲ 65.6% |
| Equity and liabilities | ||||||||
| Total equity and liabilities10/49 | €1.3m | €1.4m | €1.5m | €1.6m | €1.5m | €1.5m | €1.4m | ▼ 4.2% |
| Equity10/15 | €1.1m | €1.2m | €1.3m | €1.4m | €1.4m | €1.4m | €1.4m | ▼ 1.9% |
| Contributions10/11 | €0.02m | - | - | €0.01m | €0.01m | €0.01m | €0.01m | = |
| Reserves13 | €1.1m | €1.2m | €1.3m | €1.4m | €1.4m | €1.4m | €1.4m | ▼ 1.9% |
| Distributable reserves133 | - | - | - | €1.4m | €1.4m | €1.4m | €1.4m | ▼ 1.9% |
| Amounts payable17/49 | €0.1m | €0.1m | €0.1m | €0.1m | €0.06m | €0.06m | €0.03m | ▼ 57.5% |
| Amounts payable after more than one year17 | €0.006m | - | - | - | - | - | - | - |
| Amounts payable within one year42/48 | €0.1m | €0.1m | €0.1m | €0.1m | €0.06m | €0.06m | €0.03m | ▼ 57.5% |
| Trade debts44 | €0.07m | €0.06m | €0.08m | €0.06m | €0.02m | €0.04m | €0.009m | ▼ 75.2% |
| Suppliers440/4 | - | - | - | €0.06m | €0.02m | €0.04m | €0.009m | ▼ 75.2% |
| Taxes, remuneration and social security45 | - | - | - | €0.06m | €0.02m | €0.02m | €0.01m | ▼ 45.4% |
| Taxes450/3 | - | - | - | €0.06m | €0.02m | €0.02m | €0.01m | ▼ 45.4% |
| Other amounts payable47/48 | - | - | - | €0.02m | €0.02m | €0.003m | €0.005m | ▲ 71.9% |
| Accrued charges and deferred income492/3 | - | - | - | €22 | €23 | €39 | €44 | ▲ 13.2% |
| Line | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €161,763 | €154,845 | €192,642 | €180,813 | €134,878 | €95,521 | €92,739 | ▼ 2.9% |
| + Depreciation and write-downs630 | €17,055 | €16,637 | €17,514 | €18,119 | €15,760 | €17,111 | €16,120 | ▼ 5.8% |
| Operating cash flow (approximation) | €178,817 | €171,482 | €210,156 | €198,933 | €150,638 | €112,632 | €108,858 | ▼ 3.4% |
| Investment in fixed assets (approximation) | - | €0 | -€4,937 | €0 | -€5,765 | €0 | -€4,455 | - |
| Change in cash | - | €150,144 | €55,948 | -€50,638 | -€138,160 | -€228,025 | €87,617 | - |
A Belgian filing has no cash-flow statement. These rows are therefore an approximation, derived from the income statement and the balance-sheet moves.
Historical observation
In July 2024, 20,136 companies had the same profile as ImmunoSource has now. Two years later, 95.0% were still going and 0.2% had gone bankrupt.
- Small
- 20 years or older
- solvency 30% or more
- a profit of 5% of the balance sheet or more
95.0%
was still going
4.7%
stopped otherwise
0.2%
went bankrupt
That fits the bankruptcy probability of ImmunoSource itself: < 0.1% within 12 months.
Test of the method
The method was tested on the 497,446 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 20,136 companies, not a prediction for ImmunoSource. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Latest 10 of 31 filings with the National Bank
| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 31-07-2025 | micro format | 10-02-2026 | 2026-00037577 | |
| 31-07-2024 | micro format | 20-02-2025 | 2025-00039058 | |
| 31-07-2023 | micro format | 28-02-2024 | 2024-00037928 | |
| 31-07-2022 | micro format | 28-02-2023 | 2023-00034540 | |
| 31-07-2021 | micro format | 11-02-2022 | 2022-05500475 | |
| 31-07-2020 | micro format | 26-02-2021 | 2021-06500059 | |
| 31-07-2019 | abbreviated format | 28-02-2020 | 2020-06100595 | |
| 31-07-2018 | abbreviated format | 20-02-2019 | 2019-05700161 | |
| 31-07-2017 | abbreviated format | 31-01-2018 | 2018-04400088 | |
| 31-07-2016 | abbreviated format | 03-02-2017 | 2017-04000548 |
Board & ownership
Directors
Directors
1 director
SNYERS Patrick
Current
Director · listed in the 2025 annual accounts, filed on 10-02-2026
Owners and capital
Owners
Network & group
ImmunoSource shares no director with another company.
Companies at the same address
1 other companyConnections & network
1 current directorThe network starts from the directors of ImmunoSource. Every other company they run is a node.
This company
Company
Director
Shareholding
+N: links not shown yet
Click a node to look further, drag to arrange, zoom with the mouse wheel.
Timeline
Acts, filings and financial milestones
Deadline for the 2026 accounts:
2026
10-02
micro format · 18 days before the deadline
2025
31-07
Financial
Liquidity more than doubledcurrent ratio 53.11
The current ratio rises from 23.38 to 53.11. Short-term debt falls from €61,699 to €26,194.
20-02
micro format · 8 days before the deadline
2024
28-02
micro format · 1 day before the deadline
2023
31-07
Financial
Liquidity more than doubledcurrent ratio 24.20
The current ratio rises from 10.94 to 24.20. Short-term debt falls from €135,099 to €59,159.
28-02
micro format · on the deadline day
2022
11-02
micro format · 17 days before the deadline
2021
31-07
Financial
Highest result from 2019 to 2025net €192,642 ▲24.4%
The net result of €192,642 is the highest of those years.
26-02
micro format · 2 days before the deadline
2020
28-02
abbreviated format · 1 day before the deadline
2019
20-02
abbreviated format · 8 days before the deadline
2018
31-01
abbreviated format · 28 days before the deadline
2017
03-02
abbreviated format · 25 days before the deadline
1993
05-11
Gazette deed
Incorporation
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
Sources:Publications in the Belgian Official GazetteFilings with the National Bank
History
Company details
Register details
Identity
KBO recordName
ImmunoSource in Dutch
Enterprise number
0451.125.125
LEI code
967600HHX60JK2Z54B86
live in the LEI register
Legal form
Private limited company
Status
Active, normale toestand
Founded
15-10-1993
Entity type
Legal entity
Registered office and establishments
Registered office
Eugeen Van de Vellaan 2, 2970 Schilde, Belgium
Establishment unit
IMMUNOSOURCE, Ruiterslaan 29, 2980 Zoersel since 29-10-1993 · unit number 2.064.166.631 46851 Wholesale of industrial chemicals
Activities
NACEBEL 202596999
Other personal services main activity
Codes under NACEBEL 2008
96099
Personal service activities main activity
Codes under NACEBEL 2003
93053
main activity
Joint committees
116 Paritair Comité voor de scheikundige nijverheid
207 Paritair Comité voor de bedienden uit de scheikundige nijverheid annual accounts 31-07-2025
Invoicing and payment
VAT number
BE 0451.125.125
Financial year and general meeting
Accounts at the NBBFinancial year end
31-07
Sites & property
Location
Buildings and parcels at the addresses
Ground area
1,375 m²
Building footprint
276 m²
Building volume
1,445 m³
Tallest building: 13.4 m.
| Cadastral parcel | Region | Area | Buildings | Height / floors |
|---|---|---|---|---|
| 11017A0586/00G000 | Flanders | 1,080 m² | 1 · 255 m² | 7.9 m · 2 |
| 11039D0151/00A003 | Flanders | 294 m² | 1 · 21 m² | 13.3 m · 4 |